Amylyx Pharmaceuticals (AMLX) Expected to Announce Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is projected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.49) per share for the quarter.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $3.00 on Tuesday. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $19.95. The business has a fifty day moving average price of $3.67 and a 200-day moving average price of $3.81. The firm has a market capitalization of $205.65 million, a P/E ratio of -0.79 and a beta of -0.54.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AMLX shares. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.33.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the sale, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the completion of the transaction, the chief executive officer now owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,000 shares of company stock worth $84,142 over the last 90 days. Corporate insiders own 11.70% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.